Abstract library

21 results for "Sasano".
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
#2742 Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents
Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Oriol Casanovas
#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Alberto Carmona-Bayonas
#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study
Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Mercedes Mitjavila Casanovas
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#226 Insulin-like Growth Factor-1 Receptor (IGF-1R) and its Inhibition in Non-functioning Neuroendocrine Tumors
Introduction: Insulin-like growth factor-1 receptor (IGF-1R) was reported to be expressed in NET (neuroendocrine tumor) cells but its biological roles and activation status in non-functioning NET are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Sasano H, Iida S, Ono K, Nakamura Y, ...
#729 Neuroendocrine Neoplasms of the Ampulla of Vater: Clinicopathological Analysis of Nine Cases
Introduction: Neuroendocrine neoplasms (NEN) of the ampulla of Vater (AV) are rare and heterogeneous and little is known about their biological behavior.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Luis Perez-Casanova
#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Luis Pérez-Casanova